These studies are designed to test the novel idea that Sprouty-2 (SPRY2), an intracellular regulator of receptor tyrosine kinase-induced signaling, is a central gatekeeper restricting colonic epithelial repair responses including protective changes in secretory differentiation and wound healing. Our preliminary data show that SPRY2 is downregulated by inflammation in the colonic epithelium. This appears to be a protective or compensatory response, as mice with intestinal epithelium-specific SPRY2 deletion are resistant to dextran sulfate sodium (DSS)-induced colitis. Furthermore, these mice display altered intracellular signaling, elevated interleukin IL-33 levels, more tuft cells, and increased mucus production. Thus, a regulated loss of SPRY2 may be an important, potentially exploitable, mechanism contributing to repair of the colonic epithelial barrier following an insult. In this project, we will test the hypothesis that colitis-induced loss of SPRY2 releases normal homeostatic inhibition of intracellular signaling to promote protective epithelial and epithelial- mesenchymal responses.
Aims of the study are (1) define the influence of SPRY2 on colonic secretory cell differentiation and function; (2) test the role of SPRY2 in epithelial wound repair, and (3) determine whether SPRY2 downregulation drives recovery from colitis. We will test the central hypothesis with coordinated in vitro and in vivo models including human and mouse primary colonic epithelial culture, cell culture models, and in vivo colitis using conditional knockout mice or mice in which SPRY2 levels are manipulated through nanoparticle-delivered expression constructs.

Public Health Relevance

These studies are designed to advance our understanding of novel molecular mechanisms that promote protective and repair responses in the colon during injury and inflammation. They will define cellular targets and pathways that could be leveraged for future therapies, and thus are important and directly relevant for inflammatory bowel diseases and potentially other intestinal pathologies involving damage to the epithelial barrier.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK119694-02
Application #
9997911
Study Section
Gastrointestinal Mucosal Pathobiology Study Section (GMPB)
Program Officer
Greenwel, Patricia
Project Start
2019-08-20
Project End
2023-05-31
Budget Start
2020-06-01
Budget End
2021-05-31
Support Year
2
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Children's Hospital of Los Angeles
Department
Type
DUNS #
052277936
City
Los Angeles
State
CA
Country
United States
Zip Code
90027